DIA Biosimilars 2013

Savient Pharmaceuticals

Savient appoints new CEO, cuts work force by 35%

Monday, July 9, 2012 02:37 PM

Savient Pharmaceuticals, a specialty biopharmaceutical company based in East Brunswick, N.J., has appointed Louis Ferrari, current executive vice president and president North American commercial operations, to the role of president and CEO.

More... »

Cenduit: Now with Patient Reminders

Dendreon appoints three to executive team

Wednesday, March 14, 2012 09:10 AM

Seattle, Wash.-based Dendreon has appointed three new members to its executive team:

More... »

CRF Health – eCOA Forum

Dendreon announces CEO and chairman succession plan

Wednesday, February 1, 2012 03:41 PM

Dendreon’s board of directors has elected John H. Johnson president and CEO, succeeding Mitchell H. Gold, M.D., who has served as both for nearly a decade.

More... »

Savient signs agreement with U.S. Dept. of Veterans Affairs

Tuesday, March 29, 2011 11:56 AM

New Jersey-based Savient Pharmaceuticals signed a deal to supply the U.S. Department of Veterans Affairs with Krystexxa, its new gout drug, along with its weight-gain medication, Oxandrin, for five years, according to Fierce Pharma.

More... »

CenterWatch Drugs in Clinical Trials Database Library. Drug intelligence right at your fingertips.
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

September 30

Novartis-Walgreens pilot study blurring the line between retail pharmacy, investigative site

CISCRP to launch traveling science museum exhibit to demystify clinical trial participation

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

October

New growth and decline in Asia clinical trials
South Korea, Japan, China see big growth in 1572s, while India posts huge drop

Harnessing Big Data to transform clinical trials
From protocol to patient recruiting, data analytics can yield valuable insights

Already a subscriber?
Log in to your digital subscription.

Purchase the October issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

September

Sponsors look to collaborate on comparator drugs
Co-therapies, comparators are in 60% of studies, cost $25m per company a year

Early adopters implement risk-based monitoring pilot programs
Experiments aim to offer long-term solutions, despite short-term uncertainties

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs